Literature DB >> 11423461

Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment.

R M Conway1, W C Chua, C Qureshi, F A Billson.   

Abstract

AIMS: To describe features influencing the management of primary iris melanoma and report the outcome of conservative surgical treatment of patients diagnosed with this condition in a tertiary referral academic setting over a 20 year period.
METHODS: Retrospective non-comparative case series of consecutive patients diagnosed with iris melanoma from 1980-2000 using medical records from the University of Sydney Department of Ophthalmology and NSW Cancer Registry
RESULTS: 51 cases were identified. The most common presentation was growth of a previously noted pigmented lesion. Initial management was either observation or local resection (two had enucleations) with iris reconstruction where possible (23.8%). The mean follow up was 8.7 years (range 1-17 years). Vision of 6/12 or better was maintained in the majority (78.6%) treated by local resection. Pupil reconstruction significantly reduced reported postoperative glare symptoms. Four patients had features suggestive of local recurrence and there was no documented metastatic disease or death from iris melanoma in this series. Histologically, the majority were spindle B cell melanomas. Clinical features including prominent tumour vascularity, rapid growth, and heterogeneous pigmentation were each significantly associated with an epithelioid cell component. Involvement of the iridocorneal angle was frequently associated with ciliary body invasion.
CONCLUSIONS: Management decisions for iris melanoma will depend on the clinical features. Mixed or epithelioid histology is more likely in the presence of two or more of the features of malignancy and may justify earlier intervention. When treatment is undertaken, local resection achieves long term tumour clearance with an acceptable morbidity. In resecting iris melanoma, careful assessment for iridocorneal angle involvement is important in treatment planning. Iris reconstruction has a useful role in reducing postoperative photophobia.

Entities:  

Mesh:

Year:  2001        PMID: 11423461      PMCID: PMC1724056          DOI: 10.1136/bjo.85.7.848

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  23 in total

1.  The prognosis of primary tumors of the iris treated by iridectomy.

Authors:  B RONES; L E ZIMMERMAN
Journal:  AMA Arch Ophthalmol       Date:  1958-08

2.  Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

3.  Local resection versus enucleation in the management of choroidal melanoma.

Authors:  W S Foulds; B E Damato; R L Burton
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

4.  Excision of uveal melanomas: a 15-year experience.

Authors:  G B Kara
Journal:  Ophthalmology       Date:  1979-06       Impact factor: 12.079

5.  Iris melanomas.

Authors:  L J Geisse; D M Robertson
Journal:  Am J Ophthalmol       Date:  1985-06-15       Impact factor: 5.258

6.  Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors.

Authors:  C L Shields; J A Shields; M B Shields; J J Augsburger
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

7.  The differential diagnosis of malignant melanoma of the iris. A clinical study of 200 patients.

Authors:  J A Shields; G E Sanborn; J J Augsburger
Journal:  Ophthalmology       Date:  1983-06       Impact factor: 12.079

8.  Ciliary body and choroidal melanomas treated by proton beam irradiation. Histopathologic study of eyes.

Authors:  J M Seddon; E S Gragoudas; D M Albert
Journal:  Arch Ophthalmol       Date:  1983-09

9.  Are most iris "melanomas' really nevi? A clinicopathologic study of 189 lesions.

Authors:  F A Jakobiec; G Silbert
Journal:  Arch Ophthalmol       Date:  1981-12

10.  Fluorescence angiographical studies in the diagnosis and follow-up of tumors of the iris and ciliary body.

Authors:  U Demeler
Journal:  Adv Ophthalmol       Date:  1981
View more
  18 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

Review 2.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

3.  Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Authors:  Aline I Riechardt; Bettina Karle; Dino Cordini; Jens Heufelder; Volker Budach; Antonia M Joussen; Johannes Gollrad
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

Review 4.  Rare presentations of primary melanoma and special populations: a systematic review.

Authors:  Lisa A Kottschade; Travis E Grotz; Roxana S Dronca; Diva R Salomao; Jose S Pulido; Nabil Wasif; James W Jakub; Sanjay P Bagaria; Riten Kumar; Judith S Kaur; Shane Y Morita; Steven L Moran; Jesse T Nguyen; Emily C Nguyen; Jennifer L Hand; Lori A Erickson; Jerry D Brewer; Christian L Baum; Robert C Miller; David L Swanson; Val Lowe; Svetomir N Markovic
Journal:  Am J Clin Oncol       Date:  2014-12       Impact factor: 2.339

5.  Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.

Authors:  M Tsimpida; J Hungerford; A Arora; V Cohen
Journal:  Eye (Lond)       Date:  2011-09-23       Impact factor: 3.775

6.  [Iridal color changing in ocular masquerade syndrome].

Authors:  S Waibel; K Pillunat; L Pillunat
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

7.  Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.

Authors:  Aline I Riechardt; Julian P Klein; Dino Cordini; Jens Heufelder; Matus Rehak; Ira Seibel; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-20       Impact factor: 3.117

Review 8.  Ocular melanoma: an overview of the current status.

Authors:  Predrag Jovanovic; Marija Mihajlovic; Jasmina Djordjevic-Jocic; Slobodan Vlajkovic; Sonja Cekic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

9.  Diffuse iris melanoma: Report of a case with review of the literature.

Authors:  Simon E Skalicky; Michael Giblin; R Max Conway
Journal:  Clin Ophthalmol       Date:  2007-09

10.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.